Interaction Between a Calcimimetic Agent and the Renin Angiotensine Aldosterone System

Relationship Between Calcimimetic and the RAAS Clinical Trial

Official title:

Evaluation of the Interaction Between a Calcimimetic Agent (Cinacalcet) and the Renin Angiotensine Aldosterone System in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01519037
• Other study ID #: 2011DR4219
• Status: Completed
• Phase: N/A
• Start date: January 2012
• Est. completion date: June 2014

Study information

• Verified date: March 2020
• Source: Centre Hospitalier Universitaire Vaudois
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate, in healthy volunteers, the acute modulating effect of cinacalcet on the RAAS, the effect of furosemide on parathyroid secretion of PTH and the interaction between furosemide and cinacalcet on parathyroid hormone secretion.

Description:

The clinical trial will be monocentric (Service of Nephrology and Hypertension at CHUV, Lausanne) and will include 24 patients. The volunteers will get involved after inclusion (Inclusion Visit) in a crossover study over two double-blind periods. The order of the two periods (placebo or cinacalcet) will be randomized. Each period comprises 3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: June 2014
• Est. primary completion date: June 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy subject

• Male

• Age > 18 and < 45 years old

• Caucasian

• Non-smoker

• BMI >18 and < 25 Kg/m2

• Normal clinical examination

• ECG normal, 12 leads

• Systolic arterial pressure (SBP) =100 = 139 mmHg and diastolic arterial pressure (DBP) =50 = 89 mmHg (after 5 minutes lying down, 3 measurements at 2-minute intervals; Omron machine; left arm)

• Heart rate (HR) = 45 = 90 beats/min

• Subject capable of understanding the written information and the written consent form.

• Subject must have given written, dated and signed consent before starting any trial procedure.

Exclusion Criteria:

• • Female

• Age < 18 or > 45 years old

• Electrolyte disturbances, defined as any sodium, potassium, total or ionized calcium, phosphate or magnesium value outside of the laboratory's reference values (at the Inclusion Visit).

• Seropositive for HIV, HBV or HCV (at the Inclusion Visit).

• Positive detection of drugs in urine (opiates, cannabinoids, cocaine, benzodiazepines, amphetamines or barbiturates) (at the Inclusion Visit).

• Fall in SBP > or DBP > 10 mmHg after standing for 1 minute or any clinical manifestation of postural hypotension (at the Inclusion Visit).

• Any history of diseases or clinically significant conditions which may be gastrointestinal (such as gastritis or gastric ulcer), respiratory, psychiatric, neurological (medical history of convulsions), renal, hepatic or cardiac or other diseases/conditions or abnormal physical signs which may interfere with the study's objectives. The investigator may disqualify any subject for a valid medical or psychiatric reason.

• Ongoing involvement or in the 60 days prior to the Inclusion Visit in another research study.

• Chronic use of any medication (prescribed or not) during the 4 weeks prior to the Inclusion Visit (only the use of medications such as paracetamol for headaches will be tolerated at the lowest dose possible.

• Use of any medication known as CYP P450 3A4 inhibitors during the 12 weeks prior to the Inclusion Visit (amiodarone, diltiazem, verapamil, ketoconazole, itraconazole, voriconazole, posaconazole, fluconazole, miconazol, ritonavir, nelfinavir, amprenavir, indinavir, atazanavir, erythromycin, clarithromycin, josamycin, telithromycin)

• Donation of blood, plasma and/or marrow in the 3 months prior to the Inclusion Visit

• Medical history of dependence on drugs or alcohol abuse as defined by the DSM IVR, criteria for diagnosing drug and alcohol abuse and dependence on drugs.

• Medical history of intolerant reactions to cinacalcet or furosemide (or derivatives of sulfamides)

Related Conditions & MeSH terms

• Relationship Between Calcimimetic and the RAAS

Intervention

Drug:
• Cinacalcet 60 MG
one dose of oral cinacalcet, 60mg
• Placebo oral tablet
one tablet of placebo

Locations

Country	Name	City	State
Switzerland	CHUV, service de néphrologie/hypertension	Lausanne	Vaud

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Vaudois	Swiss National Science Foundation

Country where clinical trial is conducted

Switzerland, 

References & Publications (2)

Maillard MP, Tedjani A, Perregaux C, Burnier M. Calcium-sensing receptors modulate renin release in vivo and in vitro in the rat. J Hypertens. 2009 Oct;27(10):1980-7. doi: 10.1097/HJH.0b013e32832f0d22. — View Citation

Muller ME, Forni Ogna V, Maillard M, Stoudmann C, Zweiacker C, Anex C, Wuerzner G, Burnier M, Bonny O. Furosemide stimulation of parathormone in humans: role of the calcium-sensing receptor and the renin-angiotensin system. Pflugers Arch. 2015 Dec;467(12) — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect of cinacalcet compared to placebo on plasma renin activity	to determine the acute effect of a single high dose of cinacalcet compared to placebo on plasma renin activity (PRA), under RAAS-stimulating conditions (low sodium diet, furosemide injection) by PRA plasma measure	up to 36 days
Secondary	effect of cinacalcet administered as single dose (compared to placebo) on plasma aldosterone and on hemodynamics	to determine the effect of cinacalcet administered as single dose (compared to placebo) on plasma aldosterone and on hemodynamics (blood pressure, heart rate), under RAAS stimulating conditions (low sodium diet, furosemide injection).	up to 36 days